Lactobacillus casei ( DrugBank: Lactobacillus casei )

3 diseases

ID	Disease name (Link within this page)	Number of trials
6	Parkinson disease	1
97	Ulcerative colitis	2
296	Biliary atresia	1

6. Parkinson disease

Clinical trials : 2,307 / Drugs : 2,007 - (DrugBank : 349) / Drug target genes : 188 - Drug target pathways : 199

diseases per page:

Showing 1 to 1 of 1 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04293159 (ClinicalTrials.gov)	May 14, 2019	19/2/2020	Effect of Probiotic on Constipation in Patients With Parkinson's Disease	Effect of Probiotic on Constipation and on Neuropsychological Performance in Patients With Parkinson ...	Parkinson Disease;Constipation	Dietary Supplement: Lactobacillus casei DG (Enterolactis duo®)	University of Salerno	Roberto Erro;Maria Teresa Pellecchia;Antonella Santonicola;Carolina Ciacci	Recruiting	18 Years	75 Years	All	30	N/A	Italy

Clinical trials : 2,630 / Drugs : 1,459 - (DrugBank : 265) / Drug target genes : 144 - Drug target pathways : 202

diseases per page:

Showing 1 to 2 of 2 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	ChiCTR2000033953	2020-07-01	2020-06-18	Effect of the probiotic on symptoms in patients with ulcerative colitis (UC)	Effect of the probiotic on symptoms in patients with ulcerative colitis (UC)	Ulcerative colitis	Placebo group:Maltodextrin;experimental group 1:Lactobacillus plantarum CCFM8610;experimental group ...	Jiangnan University	NULL	Pending			Both	Placebo group:20;experimental group 1:20;experimental group 2:20;experimental group 3:20;		China
2	NCT03136419 (ClinicalTrials.gov)	October 31, 2016	5/4/2017	Microbiota and Immune microEnvironment in Pouchitis	Microbiota and Immune microEnvironment in Pouchitis: Randomized Controlled Trial Oral Administration ...	Pouchitis;Ulcerative Colitis;Ileal Pouch	Dietary Supplement: Lactobacillus casei DG;Dietary Supplement: Placebo	University of Padova	NULL	Recruiting	18 Years	100 Years	All	32	N/A	Italy

Clinical trials : 71 / Drugs : 70 - (DrugBank : 39) / Drug target genes : 35 - Drug target pathways : 60

diseases per page:

Showing 1 to 1 of 1 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00166868 (ClinicalTrials.gov)	December 2003	12/9/2005	Use of Probiotics to Prevent Cholangitis in Children With Biliary Atresia After the Kasai Portoenter ...	Use of Probiotics to Prevent Cholangitis in Children With Biliary Atresia	Biliary Atresia	Drug: Lactobacillus casei rhamnosus (Lcr35);Drug: Neomycin	National Taiwan University Hospital	NULL	Completed	4 Months	3 Years	Both	30	N/A	Taiwan